The Bachmann-Strauss Dystonia and Parkinson’s Disease Program of Excellence at UAB, located on the 3rd floor of the Sparks Center Building at 1720 7th Avenue South. The mission of the program is to integrate the elements of research and clinical care for patients with Dystonia and Parkinson disease, this will include community outreach, coordination of care, and facilitation of access to multidisciplinary treatment including movement disorder specialists, physical, ocupational and speech therapy, botulinum toxin treatment, neurosurgical treatment, and genetic counseling. Furthermore, the program will enhance the access of patients to clinical trials in dystonia and Parkinson disease, and enable conduct of trials which will advance the fields. The program will also facilitate the interactions between clinicians, basic scientists, and members of the community, and promote cross-culture efforts to translate new discoveries while training the next generation of dystonia and Parkinson disease clinicians and scientists through support of clinical and basic/translational fellowships.
UAB joins Beth Israel Hospital, University of California San Francisco and the University of Florida as one of these named programs.
Meet Our Team
David G. Standaert, M.D, Ph.D.
John Whitaker Professor and Chair
Dr. Standaert is a clinician-scientist with a long-standing commitment to research in dystonia and P.D. Dr. Standaert joined UAB in 2006, as Director of CNET and Vice Chair of the Neurology Department. In August of 2011, he was appointed Chair of the UAB Department of Neurology
Natividad P. Stover, M.D.
Associate Professor of Neurology
Dr. Stover is an experienced movement disorders clinician, with fellowship training at Emory, who has been a member of the UAB faculty since 2003. She has very extensive clinical trial experience, having served as site PI for over 40 trials of novel therapies for PD and dystonia. She also has substantial experience with the use of toxin therapies for dystonia, and is one of the primary practitioners offering this treatment at UAB.